Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA BLADDR 2021 | New agents and novel trials in advanced UC

Petros Grivas • 19 Oct 2021
PROSCA BLADDR 2021
Genitourinary Cancer Urothelial Carcinoma Avelumab Enfortumab vedotin Erdafitinib Pembrolizumab Sacituzumab govitecan
EV-301 TROPHY-U-01

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, discusses new agents and novel trials in advanced urothelial carcinoma (UC), including the use of antibody-drug conjugates, FGFR inhibitors and the promise of combination therapies and biomarkers. This interview took place at the PROSCA/BLADDR 2021 congress.

More from Petros Grivas

Ask the Expert: Petros Grivas answers your bladder cancer questions at ESMO 2025
18:47
Ask the Expert: Petros Grivas answers your bladder cancer questions at ESMO 2025
Petros Grivas • 31 Oct 2025
Neoadjuvant pembrolizumab + MVAC in nonurothelial muscle-invasive bladder cancer: Phase II trial
2:23
Neoadjuvant pembrolizumab + MVAC in nonurothelial muscle-invasive bladder cancer: Phase II trial
Petros Grivas • 3 Sep 2025
Phase III clinical trials exploring targeted combination therapies for patients with UC
1:08
Phase III clinical trials exploring targeted combination therapies for patients with UC
Petros Grivas • 20 Oct 2023
Phase Ib trial of bintrafusp alfa for advanced urothelial cancer
1:39
Phase Ib trial of bintrafusp alfa for advanced urothelial cancer
Petros Grivas • 20 Oct 2023

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals